KALAMAZOO — An agreement with a Canadian company will significantly expand sales and marketing efforts forArmune Bioscience Inc.and its new blood test for prostate cancer that hit the market this year.
Under the co-marketing deal, Quebec City-basedAeterna Zenteris Inc.will market Armune’s Apifiny blood test alongside its own products as it meets with health systems and large medical groups across the U.S. The company will also begin moving the test into Europe, potentially in 2016.
“We’re going to work together to commercialize Apifiny,” said David Esposito, CEO of Kalamazoo-based Armune. “It significantly expands our marketing efforts around Apifiny in the U.S. and opens the door for our European expansion.”